ImmunityBio, Inc. (IBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.93+7.72%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · IBRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 416.1% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 476.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
IBRX — earnings in line
Dated 2026-08-04
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filings of the Company made under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general i…
Why it matters: A filing would move ANKTIVA toward a possible use in BCG-naïve bladder cancer. A missed filing would delay that step.
Supportive ifImmunityBio submits the QUILT-2.005 sBLA in 2026 for BCG-naïve NMIBC CIS.
Worry ifThe company reports that the 2026 filing is delayed or will not proceed.
Why it matters: FDA guidance and a clear filing plan would advance a second possible U.S. BCG source. The strain is not FDA-approved.
Supportive ifThe company names an FDA-agreed path and a target date for a Tokyo-172 BCG BLA.
Worry ifThe company reports no FDA path, no target date, or a halt to the BLA effort.
Why it matters: Q2 revenue rose 15% from Q1. Another increase would extend the run of quarter-to-quarter growth.
Supportive ifOn November 3, Q3 net product revenue is above Q2's $50.7 million.
Worry ifOn November 3, Q3 net product revenue is $50.7 million or lower.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$279 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $765 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,234 loss on $10,000 · 42.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.